A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Abstract Text:

An amphipathic alpha-helical peptide (C5A) derived from the membrane anchor domain of the hepatitis C virus (HCV) NS5A protein is virocidal for HCV at submicromolar concentrations in vitro. C5A prevents de novo HCV infection and suppresses ongoing infection by inactivating both extra- and intracellular infectious particles, and it is nontoxic in vitro and in vivo at doses at least 100-fold higher than required for antiviral activity. Mutational analysis indicates that C5A's amphipathic alpha-helical structure is necessary but not sufficient for its virocidal activity, which depends on its amino acid composition but not its primary sequence or chirality. In addition to HCV, C5A inhibits infection by selected flaviviruses, paramyxoviruses, and HIV. These results suggest a model in which C5A destabilizes viral membranes based on their lipid composition, offering a unique therapeutic approach to HCV and other viral infections.

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Proceedings of the National Academy of Sciences of

VOLUME: 105

Page Numbers: 3088-93

Journal Abbreviation: Proc. Natl. Acad. Sci. U.S.A.

ISSN: 1091-6490

DAY: 19

MONTH: 02

YEAR: 2008

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7505876

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

AFFILIATION: Departments of Molecular and Experimental Medicine, Chemistry, and Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Country: United States

AGENCY: United States NIGMS

GRANT: GM52190

ACRONYM: GM

MEDLINETA: Proc Natl Acad Sci U S A

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro Related Publications

• A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.
• Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion.
• Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles.
• Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells.
• Endophthalmitis: gram positive ethiological agents and susceptibility to glycopeptides.
• Immunobiology and pathogenesis of viral hepatitis.
• Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.
• PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.
• Persistent hepatitis C virus infection in vitro: coevolution of virus and host.
• Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.